专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明申请

WO2004014952A3 SPECIFIC PROBNP(1-108) ANTIBODIES FOR DIAGNOSING HEART FAILURE 审中-公开
标题翻译：特异性PROBNP（1-108）诊断心脏失败的抗体
公开(公告)号：WO2004014952A3
公开(公告)日：2004-04-08
申请号：PCT/FR0302483
申请日：2003-08-07
申请人： BIO RAD PASTEUR , CENTRE NAT RECH SCIENT , UNIV MONTPELLIER I , PAU BERNARD , GIULIANI ISABELLE , RIEUNIER FRANCOIS
发明人： PAU BERNARD , GIULIANI ISABELLE , RIEUNIER FRANCOIS
IPC分类号： C07K16/18 , C07K14/58 , C07K16/26 , C12N5/20 , C07K7/06 , C07K7/08 , C07K16/06 , C12N5/12 , G01N33/53 , G01N33/74
CPC分类号： C07K16/26 , C07K14/58 , C07K2317/34
摘要： The invention relates to in vitro diagnosis of heart failure. More specifically, the invention relates to specific antibodies of a peptide domain which is situated on either side of hinge region R76S77 of proBNP(1-108). In particular, the invention relates to a method of obtaining the aforementioned antibodies and to the use thereof in detecting blood proBNP(1-108) with the exception of BNP(1-76) and BNP(77-108). The invention also relates to a method of detecting blood proBNP(1-108), reagents and a kit for same.
摘要翻译：本发明涉及心力衰竭的体外诊断。更具体地，本发明涉及位于proBNP（1-108）的铰链区R76S77的任一侧上的肽结构域的特异性抗体。特别地，本发明涉及获得上述抗体的方法及其在检测血液proBNP（1-108）中的用途，BNP（1-76）和BNP（77-108）除外。本发明还涉及一种检测血液proBNP（1-108），试剂和试剂盒的方法。

2. 发明专利

AT486093T 未知
公开(公告)号：AT486093T
公开(公告)日：2010-11-15
申请号：AT03756532
申请日：2003-08-07
申请人： BIO RAD PASTEUR , CENTRE NAT RECH SCIENT , UNIV MONTPELLIER I
发明人： PAU BERNARD , GIULIANI ISABELLE , RIEUNIER FRANCOIS
IPC分类号： C07K16/18 , C07K16/26 , C07K7/06 , C07K7/08 , C07K14/58 , C07K16/06 , C12N5/12 , C12N5/20 , G01N33/53 , G01N33/74
摘要： Antibody (Ab) directed against proBNP(1-108) (A; BNP = brain natriuretic peptide), is new. Antibody (Ab) directed against proBNP(1-108) (A; BNP = brain natriuretic peptide) that: (a) recognizes specifically the sequence Arg-Ala-Pro-Arg76-Ser77-Pro (5) of (A) but does not significantly recognize the BNP peptides 1-76 and 77-108; and (b) recognizes specifically (A) circulating in human serum or plasma. Independent claims are also included for the following: (1) method for preparing Ab by immunization; (2) method for producing a hybridoma that secretes monoclonal Ab (MAb); (3) hybridoma produced by method (2); (4) MAb produced by the hybridoma of (3); (5) in vitro diagnosis of congestive heart failure in humans by using Ab or MAb to detect (A); (6) kit for detecting (A) containing Ab or MAb; (7) peptides of formulae (I)-(III); (8) peptides derived from (II) or (III) by replacing one or more of the amino acids 70, 71, 72, 79-85; (9) method for producing antibodies (Ab1) that recognize specifically sequences (II) and (III) (where X = hydrogen and Y = hydroxy) and/or (5) but not the 1-76 or 77-108 peptides, and can detect (A) in the circulation, by immunization with (I)-(III) or the derivatives of (8); (10) method for preparing hybridomas that produce Ab1; (11) Ab1 produced by method (9) or from the hybridomas of (10); (12) hybridomas of (10); (13) in vitro diagnosis of congestive heart failure in humans by using Ab1 to detect (A); (14) kit for detecting (A) containing Ab1 and/or at least one (II), (III) or the derivatives of (8). a1-X1-Arg-Ala-Pro-Arg-Ser-Pro-a2 (I); X-Tyr70-Thr-Leu-Arg-Ala-Pro-Arg76-Ser-Pro-Lys-Met-Val-Gln-Gly-Ser-Gly-Z (II); X-Tyr70-Thr-Leu-Arg-Ala-Pro-Arg76-Ser-Pro-Lys-Met-Val-Gln-Gly-Ser-Z (III) a1 = hydrogen, thiol, hydroxy, aminoxy, primary or secondary amino, aminocarbonyl, biotinyl or acetyl; X1 = 0-3 peptide amino acids (paa), optionally derived from proBNP; X2 = 0-7 paa, optionally derived from proBNP; a2 = hydroxy, amino or alkoxy; X = hydrogen, acetyl, 1-3 aa that are not part of proBNP; Z = hydroxy or 1-3 aa that are not part of proBNP.

3. 发明专利

DE60328784D1 未知
公开(公告)号：DE60328784D1
公开(公告)日：2009-09-24
申请号：DE60328784
申请日：2003-06-17
申请人： CENTRE NAT RECH SCIENT , PASTEUR INSTITUT , UNIV MONTPELLIER I
发明人： PAU BERNARD , GOURDIER ISABELLE , DEL RIO MAGUY , CRABBE LAURE
IPC分类号： G01N33/50 , G01N33/574 , A61K31/00 , A61K31/282 , A61K38/19 , A61K45/00 , A61P35/00 , A61P43/00 , C12N5/06 , C12N5/10 , C12N15/09 , C12Q1/02 , C12Q1/68 , G01N33/15 , G01N33/68
摘要： An in vitro method for detecting resistance of cancer cells (CC) to treatment with oxaliplatin (I) comprises measuring mitochondrial apoptosis of CC that have been, or could be, treated with (I), or before treatment, is new. Independent claims are also included for: (1) a similar method comprising detecting at least one mutation that indicates a defect in mitochondrial apoptosis when cells are treated with (I), particularly a mutation in a region of the Bax gene that contains a series of 8 deoxyguanines; (2) method for selecting agents (II) that inhibit resistance of CC to (I); (3) use of at least one agent (III) that stimulates mitochondrial apoptosis to prepare a composition for use in patients with (or at risk of developing) resistance to (I); (4) product/composition containing (I) and at least one (III); (5) kit for diagnosing resistance of cancer to (I); and (6) the cell HCT116/S, deposited as CNCM I-3051.

4. 发明专利

AT439596T 未知
公开(公告)号：AT439596T
公开(公告)日：2009-08-15
申请号：AT03760054
申请日：2003-06-17
申请人： CENTRE NAT RECH SCIENT , UNIV MONTPELLIER I , PASTEUR INSTITUT
发明人： PAU BERNARD , GOURDIER ISABELLE , DEL RIO MAGUY , CRABBE LAURE
IPC分类号： G01N33/50 , G01N33/574 , A61K31/00 , A61K31/282 , A61K38/19 , A61K45/00 , A61P35/00 , A61P43/00 , C12N5/06 , C12N5/10 , C12N15/09 , C12Q1/02 , C12Q1/68 , G01N33/15 , G01N33/68
摘要： An in vitro method for detecting resistance of cancer cells (CC) to treatment with oxaliplatin (I) comprises measuring mitochondrial apoptosis of CC that have been, or could be, treated with (I), or before treatment, is new. Independent claims are also included for: (1) a similar method comprising detecting at least one mutation that indicates a defect in mitochondrial apoptosis when cells are treated with (I), particularly a mutation in a region of the Bax gene that contains a series of 8 deoxyguanines; (2) method for selecting agents (II) that inhibit resistance of CC to (I); (3) use of at least one agent (III) that stimulates mitochondrial apoptosis to prepare a composition for use in patients with (or at risk of developing) resistance to (I); (4) product/composition containing (I) and at least one (III); (5) kit for diagnosing resistance of cancer to (I); and (6) the cell HCT116/S, deposited as CNCM I-3051.

5. 发明专利

AT421090T 未知
公开(公告)号：AT421090T
公开(公告)日：2009-01-15
申请号：AT01998834
申请日：2001-11-27
申请人： CENTRE NAT RECH SCIENT
发明人： PAU BERNARD , LEONETTI JEAN-PAUL , ROUBY JOELLE
IPC分类号： G01N33/50 , G01N33/68 , C12Q1/48 , G01N33/15

6. 发明专利

FR2863269A1 New peptides containing an epitope from the hinge region of pro-brain natriuretic peptide, useful as standard or control in assay of pro-BNP for diagnosis of cardiac insufficiency 未知
公开(公告)号：FR2863269A1
公开(公告)日：2005-06-10
申请号：FR0500425
申请日：2005-01-14
申请人： BIO RAD PASTEUR , CENTRE NAT RECH SCIENT , UNIV MONTPELLIER I
发明人： PAU BERNARD , GIULIANI ISABELLE KARINE , RIEUNIER FRANCOIS YVES
IPC分类号： C07K7/06 , C07K7/08 , C07K14/58 , C07K16/06 , C07K14/575 , C07K7/00 , G01N33/531 , G01N33/68 , G01N33/74
摘要： Peptides (I) that contain a pro-BNP (brain natriuretic peptide) epitope are new. Peptides of formula (I) that contain a pro-BNP (brain natriuretic peptide) epitope are new. a1-X1-ArgAlaProArgSerPro-X2-a2 (I) a1 : hydrogen, thiol, hydroxy, aminoxy, primary or secondary amino, aminocarbonyl, biotin residue or acetyl; X1 : sequence of 0-3 amino acids (aa) optionally derived from the natural sequence of proBNP(1-108); X2 : sequence of 0-8 aa optionally derived from the natural sequence of proBNP(1-108); and a2 : hydroxy, primary amino or alkoxy. Independent claims are also included for the following: (1) peptides (II) or their derivatives (IIa); and (2) kit, for detecting proBNP(1-108) in a biological sample, that contains at least one (I) or (II) as standard and/or control. X-Tyr(70)ThrLeuArgAlaProArg(76)Ser(77)ProLysMetValGlnGlySerGly(85)-Z (II) X : hydrogen, acetyl, 1-3 aa that do not belong to the sequence of proBNP(1-108); and Z : hydroxy or 1-3 aa that do not belong to the sequence of proBNP(1-108).

7. 发明专利

AU2003260595A8 Oxaliplatin anti-resistance agent 未知
公开(公告)号：AU2003260595A8
公开(公告)日：2003-12-31
申请号：AU2003260595
申请日：2003-06-17
申请人： CENTRE NAT RECH SCIENT , UNIV MONTPELLIER I , PASTEUR INSTITUT
发明人： PAU BERNARD , GOURDIER ISABELLE , RIO MAGUY DEL , CRABBE LAURE
IPC分类号： G01N33/50 , A61K31/282 , A61K38/19 , A61K45/00 , A61P35/00 , A61P43/00 , C12N5/06 , C12N5/10 , C12N15/09 , C12Q1/02 , C12Q1/68 , G01N33/15 , G01N33/574 , G01N33/68 , A61K31/00
摘要： An in vitro method for detecting resistance of cancer cells (CC) to treatment with oxaliplatin (I) comprises measuring mitochondrial apoptosis of CC that have been, or could be, treated with (I), or before treatment, is new. Independent claims are also included for: (1) a similar method comprising detecting at least one mutation that indicates a defect in mitochondrial apoptosis when cells are treated with (I), particularly a mutation in a region of the Bax gene that contains a series of 8 deoxyguanines; (2) method for selecting agents (II) that inhibit resistance of CC to (I); (3) use of at least one agent (III) that stimulates mitochondrial apoptosis to prepare a composition for use in patients with (or at risk of developing) resistance to (I); (4) product/composition containing (I) and at least one (III); (5) kit for diagnosing resistance of cancer to (I); and (6) the cell HCT116/S, deposited as CNCM I-3051.

8. 发明专利

FR2817349A1 未知
公开(公告)号：FR2817349A1
公开(公告)日：2002-05-31
申请号：FR0015332
申请日：2000-11-28
申请人： CENTRE NAT RECH SCIENT
发明人： PAU BERNARD , LEONETTI JEAN PAUL , ROUBY JOELLE
IPC分类号： G01N33/50 , C12Q1/48 , G01N33/15 , G01N33/68
摘要： The invention concerns a method for detecting a compound modulating complexing between RNA polymerase and a protein intervening during transcription, which consists in: incubating a mixture comprising RNA polymerase intervening during transcription and the compound to be detected; detecting, by a complexing test, the possible significant variation of the amount of complex formed between RNA polymerase and said protein relative to a control value corresponding to the amount of complex formed between RNA polymerase and said protein in the absence of any modulator; and deducing therefrom, when there is a significant variation as defined above, that there has been formation of a bond between said compound and RNA polymerase and/or the protein intervening during transcription, which results in a modulation of the complexing between RNA polymerase and the protein intervening during transcription.

9. 发明专利

AU2003282194B2 Specific proBNP(1-108) antibodies for diagnosing heart failure 未知
公开(公告)号：AU2003282194B2
公开(公告)日：2008-10-30
申请号：AU2003282194
申请日：2003-08-07
申请人： BIO RAD INNOVATIONS , CENTRE NAT RECH SCIENT , UNIV MONTPELLIER I
发明人： PAU BERNARD , GIULIANI ISABELLE , RIEUNIER FRANCOIS
IPC分类号： C07K16/18 , C07K14/58 , C07K16/26 , C12N5/20
摘要： Antibody (Ab) directed against proBNP(1-108) (A; BNP = brain natriuretic peptide), is new. Antibody (Ab) directed against proBNP(1-108) (A; BNP = brain natriuretic peptide) that: (a) recognizes specifically the sequence Arg-Ala-Pro-Arg76-Ser77-Pro (5) of (A) but does not significantly recognize the BNP peptides 1-76 and 77-108; and (b) recognizes specifically (A) circulating in human serum or plasma. Independent claims are also included for the following: (1) method for preparing Ab by immunization; (2) method for producing a hybridoma that secretes monoclonal Ab (MAb); (3) hybridoma produced by method (2); (4) MAb produced by the hybridoma of (3); (5) in vitro diagnosis of congestive heart failure in humans by using Ab or MAb to detect (A); (6) kit for detecting (A) containing Ab or MAb; (7) peptides of formulae (I)-(III); (8) peptides derived from (II) or (III) by replacing one or more of the amino acids 70, 71, 72, 79-85; (9) method for producing antibodies (Ab1) that recognize specifically sequences (II) and (III) (where X = hydrogen and Y = hydroxy) and/or (5) but not the 1-76 or 77-108 peptides, and can detect (A) in the circulation, by immunization with (I)-(III) or the derivatives of (8); (10) method for preparing hybridomas that produce Ab1; (11) Ab1 produced by method (9) or from the hybridomas of (10); (12) hybridomas of (10); (13) in vitro diagnosis of congestive heart failure in humans by using Ab1 to detect (A); (14) kit for detecting (A) containing Ab1 and/or at least one (II), (III) or the derivatives of (8). a1-X1-Arg-Ala-Pro-Arg-Ser-Pro-a2 (I); X-Tyr70-Thr-Leu-Arg-Ala-Pro-Arg76-Ser-Pro-Lys-Met-Val-Gln-Gly-Ser-Gly-Z (II); X-Tyr70-Thr-Leu-Arg-Ala-Pro-Arg76-Ser-Pro-Lys-Met-Val-Gln-Gly-Ser-Z (III) a1 = hydrogen, thiol, hydroxy, aminoxy, primary or secondary amino, aminocarbonyl, biotinyl or acetyl; X1 = 0-3 peptide amino acids (paa), optionally derived from proBNP; X2 = 0-7 paa, optionally derived from proBNP; a2 = hydroxy, amino or alkoxy; X = hydrogen, acetyl, 1-3 aa that are not part of proBNP; Z = hydroxy or 1-3 aa that are not part of proBNP.

10. 发明专利

CA2572681A1 CANCER TREATMENT RESISTANCE AND AGENTS MODULATING SUCH RESISTANCE 未知
公开(公告)号：CA2572681A1
公开(公告)日：2006-01-19
申请号：CA2572681
申请日：2005-07-08
申请人： CENTRE NAT RECH SCIENT , PASTEUR INSTITUT
发明人： GOURDIER ISABELLE , COQUELLE ARNAUD , KROEMER GUIDO , DUTRILLAUX BERNARD , PAU BERNARD
IPC分类号： C12Q1/68

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式